EPFL-based non-profit iM4TB has received a two-year grant of USD 769’000 from the Bill & Melinda Gates Foundation to improve the formulation of their innovative anti-tuberculosis drug PBTZ169.
EPFL-based non-profit iM4TB has received a two-year grant of USD 769’000 from the Bill & Melinda Gates Foundation to improve the formulation of their innovative anti-tuberculosis drug PBTZ169.
New publication in the Journal of Antimicrobial Agents and Chemotherapy: Pharmacodynamic analysis of PBTZ169 in Kramnik mouse model for tuberculosis shows promising results.
“Multiple drug discovery initiatives for tuberculosis are currently ongoing to identify and develop new potent drugs with novel targets in order to shorten treatment duration. One of the drug classes with a new mode of action is DprE1 inhibitors targeting an essential process in cell wall synthesis of Mycobacterium tuberculosis.
Read MoreThe third panel of the Phase Ib trial has started, aiming at evaluating the safety and tolerability of PBTZ169 at a dose of 600 mg, once a day for 14 days, in healthy volunteers.
Our colleagues from the Laboratory & Service of Clinical Pharmacology at the CHUV validated an innovative methodology using multiplex UHPLC-MS/MS for the analysis and quantification of PBTZ169, as well as five of its metabolites, in the plasma of the healthy volunteers who participated in the phase Ia clinical study.
Read MoreThe Trial Safety Board assessed the safety and tolerability parameters for panels A and B, and authorized dose escalation as no salient adverse events were observed with PBTZ169 300 mg administered b.i.d. for 2 weeks. The trial will continue with panel C (600 mg q.d.) scheduled for June 2019.
The phase Ib clinical trial with PBTZ169 (multiple ascending doses) officially started, dose escalation will be performed through four panels A, B, C and D.
To evaluate the efficacy of PBTZ169 in combination with a range of other anti-tuberculosis (TB) drugs, our collaborators from the Cole lab, at the Global Health Institute of the EPFL, used in vitroassays and mouse models in order to design a new regimen against active TB. Notably, synergism could be observed when PBTZ169 was applied in combination with bedaquiline, clofazimine, delamanid and sutezolid.
Read MorePBTZ169 has been named Macozinone. Read more here.
The phase Ia clinical trial with PBTZ169 is completed and the collected safety data, as well as pharmacokinetic and pharmacodynamic parameters, are being analyzed.
The first three investigation panels of the Phase Ia clinical trial have been successfully completed. The fourth and final panel has started and healthy male volunteer recruitment is complete.
